Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ptc Therapeutics (PTCT) Income from Continuing Operations: 2011-2024

Historic Income from Continuing Operations for Ptc Therapeutics (PTCT) over the last 14 years, with Dec 2024 value amounting to -$625.6 million.

  • Ptc Therapeutics' Income from Continuing Operations rose 114.90% to $15.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $489.4 million, marking a year-over-year increase of 190.32%. This contributed to the annual value of -$625.6 million for FY2024, which is 12.53% up from last year.
  • Per Ptc Therapeutics' latest filing, its Income from Continuing Operations stood at -$625.6 million for FY2024, which was up 12.53% from -$715.2 million recorded in FY2023.
  • Ptc Therapeutics' Income from Continuing Operations' 5-year high stood at -$487.7 million during FY2020, with a 5-year trough of -$715.2 million in FY2023.
  • Moreover, its 3-year median value for Income from Continuing Operations was -$625.6 million (2024), whereas its average is -$634.5 million.
  • As far as peak fluctuations go, Ptc Therapeutics' Income from Continuing Operations plummeted by 93.86% in 2020, and later climbed by 12.53% in 2024.
  • Ptc Therapeutics' Income from Continuing Operations (Yearly) stood at -$487.7 million in 2020, then dropped by 7.42% to -$523.9 million in 2021, then declined by 7.40% to -$562.7 million in 2022, then declined by 27.12% to -$715.2 million in 2023, then climbed by 12.53% to -$625.6 million in 2024.